STOCK TITAN

Abeona (ABEO) Insider Sells 41,913 Shares; 9,366 More Proposed

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Abeona Therapeutics (ABEO) Form 144: An insider notice shows a proposed sale of 9,366 shares of common stock to be executed on 09/29/2025 through Stifel Nicolaus. The filing states these shares were acquired as restricted stock units on 09/28/2025 and the aggregate market value of the proposed sale is listed as $50,516.00. The filing also discloses three recent sales by the same person, Joseph Vazzano, totaling 41,913 shares sold on 07/09/2025, 07/22/2025, and 09/29/2025 with gross proceeds of $148,799.00, $9,974.63, and $110,358.00 respectively. The filer certifies no undisclosed material adverse information.

Positive

  • Form 144 filed and broker identified, indicating procedural compliance with Rule 144 reporting requirements
  • Seller attests to not possessing undisclosed material adverse information

Negative

  • Insider sold 41,913 shares in the past three months, indicating notable insider liquidity
  • Proposed sale is of shares acquired as RSUs one day earlier, suggesting immediate monetization of recent grants

Insights

TL;DR: Insider plans to sell newly vested RSUs and has executed multiple recent sales; activity is notable but not necessarily material.

The filing documents a proposed sale of 9,366 shares (RSUs vested 09/28/2025) with an aggregate market value of $50,516 executed via Stifel Nicolaus on 09/29/2025. Historical sales by the same individual total 41,913 shares in the past three months with combined gross proceeds of $268,931.63. This shows active insider liquidity events rather than acquisition or disposition tied to a corporate transaction. From a market-impact perspective, the single proposed sale size is small relative to the reported 51,278,539 shares outstanding, implying limited dilution or market pressure from this single notice.

TL;DR: Disclosure follows Rule 144 mechanics; statement affirms no material nonpublic information is known to the seller.

The form includes the mandatory attestation that the seller is not aware of undisclosed material adverse information and notes the securities were acquired as RSUs from the issuer. The filing records payment as cash and identifies the broker. The disclosure appears procedural and compliant with Rule 144 reporting requirements without additional governance issues disclosed in the form itself.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the ABEO Form 144 disclose?

The filing discloses a proposed sale of 9,366 shares on 09/29/2025 valued at $50,516.00, acquired as RSUs on 09/28/2025.

Who is the seller named in the ABEO filing?

The filing lists transactions by Joseph Vazzano, including past sales and the current proposed sale submitted through Stifel Nicolaus.

How many shares has the insider sold in the past three months?

The filing shows three sales totaling 41,913 shares on 07/09/2025, 07/22/2025, and 09/29/2025.

What broker is handling the proposed sale for ABEO?

The proposed sale is to be executed through Stifel Nicolaus & Company Inc.

What is the number of shares outstanding used in the filing?

The form reports 51,278,539 shares outstanding.
Abeona Therapeut

NASDAQ:ABEO

ABEO Rankings

ABEO Latest News

ABEO Latest SEC Filings

ABEO Stock Data

295.34M
48.61M
5.78%
73.58%
17.61%
Biotechnology
Pharmaceutical Preparations
Link
United States
CLEVELAND